Open Society Voices

Newsletter Signup

Sign up to receive updates from the Open Society Foundations.

Open Society Voices

Vancouver Has Pioneered a People-First Approach to Drug Issues

March 15, 2016 | Sarah Evans

At the city’s Insite facility, people who use drugs can self-inject in a safe, supervised environment using clean equipment.

Could the “Ithaca Plan” Become a Model for Harm Reduction in America?

March 3, 2016 | Matthew Wilson

The small city of Ithaca, New York, just launched one of the most innovative approaches to drug use anywhere in the United States.

Kyrgyzstan’s Long Fight for Generic Drugs Is Finally Paying Off

February 17, 2016 | Aibek Mukambetov

With more affordable medicines, pervasive illnesses like hepatitis C can be treated more widely.

Hope for Improving Health Outcomes for Vulnerable Populations

February 9, 2016 | Kellen Russionello

A new program in California could vastly improve both health and criminal justice outcomes for the state’s most vulnerable populations.

For Funders, a Responsible Exit Is an Elusive Ideal

February 8, 2016 | Jonathan Cohen

How do foundations decide when a grantee can survive without them?

Women Speak Up Against an Archaic Abortion Law in Northern Ireland

January 27, 2016 | Kellie O’Dowd

Why is it still illegal to take a pill the World Health Organization calls an essential medicine?

To Change Drug Policy, First Change the Way You Measure It

January 21, 2016 | Dan Werb

Many governments are using the wrong metrics to evaluate their approach to drugs.

The Many Consequences of Violence Against Sex Workers

December 17, 2015 | Julia Lukomnik

Across Eastern Europe and Central Asia, a number of innovative programs are helping to counter the threats that sex workers face on a regular basis.

A Chance to Get Drug Policy Right

December 17, 2015 | Daniel Wolfe, Kasia Malinowska

In 1998, the world’s leaders hashed out a plan to create “a drug-free world.” In April, they’ll come together again—and search for a smarter way forward.

A New Look Behind the Pricing of a $1,000 Pill

December 7, 2015 | Azzi Momenghalibaf

A U.S. Senate investigation concludes that a blockbuster hepatitis C drug was priced to drive profits, not innovation. But that’s just the tip of the iceberg.

Pages